Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range

Seeking Alpha · 市场快讯 · November 5, 2026 at 1:45 AM ET

Read the full report at the original publisher.